BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has partnered with SpayVac-for-Wildlife, Inc. to test SpayVac, a long-lasting, single-dose contraceptive vaccine for Asian elephants, aiming to offer a humane solution for managing elephant populations and reducing human-elephant conflicts. The vaccine, which utilizes a patented liposome-based antigen delivery technology from BioVaxys, has shown success in previous trials with African elephants. The ongoing research in Thailand also complements BioVaxys’s broader commercial strategy to develop humane fertility control vaccines for various animal species.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
